Targeted inhibition of BCL6 is a potential therapeutic strategy for DLBCL, and BCL6 may be a good therapeutic target for DLBCL therapies and combinatorial regimens. The gene discussed is BCL6; the disease is diffuse large B-cell lymphoma.